Artículos de revistas sobre el tema "PARP1 Inhibitors"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "PARP1 Inhibitors".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Kam, Caleb M., Amanda L. Tauber, Stephan M. Levonis y Stephanie S. Schweiker. "Design, synthesis and evaluation of potential inhibitors for poly(ADP-ribose) polymerase members 1 and 14". Future Medicinal Chemistry 12, n.º 24 (diciembre de 2020): 2179–90. http://dx.doi.org/10.4155/fmc-2020-0218.
Texto completoMaluchenko, Natalya, Darya Koshkina, Anna Korovina, Vasily Studitsky y Alexey Feofanov. "Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes". Cells 11, n.º 21 (23 de octubre de 2022): 3343. http://dx.doi.org/10.3390/cells11213343.
Texto completoZientara-Rytter, Kasia, Veronique T. Baron, Junguk Park, Pavel Shashkin y Henry Zhu. "Abstract 6111: Design of a small molecule screening assay to detect DNA trapping of PARP1/2". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 6111. http://dx.doi.org/10.1158/1538-7445.am2023-6111.
Texto completoJi, Ming, Liyuan Wang, Nina Xue, Fangfang Lai, Sen Zhang, Jing Jin y Xiaoguang Chen. "The Development of a Biotinylated NAD+-Applied Human Poly(ADP-Ribose) Polymerase 3 (PARP3) Enzymatic Assay". SLAS DISCOVERY: Advancing the Science of Drug Discovery 23, n.º 6 (20 de abril de 2018): 545–53. http://dx.doi.org/10.1177/2472555218767843.
Texto completoHalazonetis, Thanos D., Michalis Petropoulos, Giacomo G. Rossetti, Angeliki Karamichali, Alena Freudenmann, Luca Iacovino, Vasilis Dionellis y Sotirios K. Sotiriou. "Abstract 1566: DNA damage generated by transcription-replication conflicts explains the synthetic lethality of PARP inhibitors with homologous recombination deficiency". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 1566. http://dx.doi.org/10.1158/1538-7445.am2023-1566.
Texto completoWang, Kai, Yizhou Wu, Lizhu Lai, Xin Wang y Shuya Sun. "How ligands regulate the binding of PARP1 with DNA: Deciphering the mechanism at the molecular level". PLOS ONE 18, n.º 8 (15 de agosto de 2023): e0290176. http://dx.doi.org/10.1371/journal.pone.0290176.
Texto completoYin, Ling y Junjie Chen. "Abstract 6098: Genome wide CRISPR screen reveals genetic vulnerabilities of next generation PARP1 inhibitor AZD5305". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 6098. http://dx.doi.org/10.1158/1538-7445.am2023-6098.
Texto completoKrastev, Dragomir B., Andrew J. Wicks y Christopher J. Lord. "PARP Inhibitors – Trapped in a Toxic Love Affair". Cancer Research 81, n.º 22 (15 de noviembre de 2021): 5605–7. http://dx.doi.org/10.1158/0008-5472.can-21-3201.
Texto completoNieborowska-Skorska, Margaret, Paulina Podszywalow-Bartnicka, Silvia Maifrede, Bac Viet Le, Monika Toma, Peter Valent, Tomasz Sliwinski et al. "PARP1 Inhibitors Eliminated Imatinib-Refractory Chronic Myeloid Leukemia Cells in Bone Marrow Microenvironment Conditions". Blood 132, Supplement 1 (29 de noviembre de 2018): 3000. http://dx.doi.org/10.1182/blood-2018-99-115041.
Texto completoTutt, Andrew. "Abstract ED12-3: ATR inhibitors and PARP1 selective PARP inhibitors". Cancer Research 83, n.º 5_Supplement (1 de marzo de 2023): ED12–3—ED12–3. http://dx.doi.org/10.1158/1538-7445.sabcs22-ed12-3.
Texto completoDemény, Máté A. y László Virág. "The PARP Enzyme Family and the Hallmarks of Cancer Part 1. Cell Intrinsic Hallmarks". Cancers 13, n.º 9 (23 de abril de 2021): 2042. http://dx.doi.org/10.3390/cancers13092042.
Texto completoShao, Zhengping, Brian J. Lee, Élise Rouleau-Turcotte, Marie-France Langelier, Xiaohui Lin, Verna M. Estes, John M. Pascal y Shan Zha. "Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo". Nucleic Acids Research 48, n.º 17 (5 de septiembre de 2020): 9694–709. http://dx.doi.org/10.1093/nar/gkaa718.
Texto completoGao, Mingming, Zhentian Li, Qipeng Fan, Jun Pan, Yu Bai, Hewen Zhang, Yu Li et al. "Abstract 1648: Discovery of a potent and selective PARP1 inhibitor and trapper with anti-tumor activities in HRD tumors". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 1648. http://dx.doi.org/10.1158/1538-7445.am2023-1648.
Texto completoNguyen, Nghia T., Anna Pacelli, Michael Nader y Susanne Kossatz. "DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy". Cancers 14, n.º 5 (23 de febrero de 2022): 1129. http://dx.doi.org/10.3390/cancers14051129.
Texto completoChen, MeiKuang, Yuan Gao, Weiya Xia, Yu-Han Wang, Jennifer K. Litton, Yu-Yi Chu, Funda Meric-Bernstam et al. "Abstract 1792: FGFR3 mediated PARP1 tyrosine 158 phosphorylation promotes PARP inhibitor resistance". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 1792. http://dx.doi.org/10.1158/1538-7445.am2022-1792.
Texto completoNam, Sujin, Jiyoung Chae, Kyung-Ok Cho, Tae-Sung Koo, Jungho Kim, Myungeun Jung, Jeongmin Kim y Eunhee Kim. "Abstract 509: DM5167, a novel selective PARP1 inhibitor, efficiently reduces growth of triple-negative breast cancers". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 509. http://dx.doi.org/10.1158/1538-7445.am2023-509.
Texto completoMurai, Junko, Shar-yin N. Huang, Benu Brata Das, Amelie Renaud, Yiping Zhang, James H. Doroshow, Jiuping Ji, Shunichi Takeda y Yves Pommier. "Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors". Cancer Research 72, n.º 21 (31 de octubre de 2012): 5588–99. http://dx.doi.org/10.1158/0008-5472.can-12-2753.
Texto completoGhosh, Avipsa, Sudhir M. Hande, Amber Balazs, Derek Barratt, Sabina Cosulich, Barry Davies, Sébastien Degorce et al. "Abstract 6302: Structure-based and property-based drug design of AZD9574, a CNS penetrant PARP1 selective inhibitor and trapper". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 6302. http://dx.doi.org/10.1158/1538-7445.am2022-6302.
Texto completoCsizmar, Clifford M., Antoine N. Saliba, Elizabeth M. Swisher y Scott H. Kaufmann. "PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword". Cancers 13, n.º 24 (20 de diciembre de 2021): 6385. http://dx.doi.org/10.3390/cancers13246385.
Texto completoMueller, Nancy, Stephen Luen, Roger Stupp, Anthony Chalmers, Baisong Huang, Massimo Squatrito, Barry Davies, Petra Hamerlik y Timothy Yap. "CTNI-03. A PHASE I/IIA, OPEN-LABEL STUDY OF THE BRAIN-PENETRANT PARP1-SELECTIVE INHIBITOR AZD9574 AS MONOTHERAPY AND IN COMBINATION IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES (CERTIS1)". Neuro-Oncology 24, Supplement_7 (1 de noviembre de 2022): vii70. http://dx.doi.org/10.1093/neuonc/noac209.270.
Texto completoKrastev, Dragomir B. y Chris Lord. "Abstract 804: Trapped PARP1 cytotoxicity is modulated by the ubiquitin-dependentsegregase p97". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 804. http://dx.doi.org/10.1158/1538-7445.am2022-804.
Texto completoYang, Chunsong, Krzysztof Wierbilowicz, Natalia M. Dworak, Song Yi Bae, Sachi B. Tengse, Nicki Abianeh, Justin M. Drake et al. "Abstract B072: Induction of PARP7 creates a vulnerability for growth inhibition by RBN2397 in prostate cancer cells". Cancer Research 83, n.º 11_Supplement (2 de junio de 2023): B072. http://dx.doi.org/10.1158/1538-7445.prca2023-b072.
Texto completoKirby, Ilsa T., Ashley Person y Michael Cohen. "Rational design of selective inhibitors of PARP4". RSC Medicinal Chemistry 12, n.º 11 (2021): 1950–57. http://dx.doi.org/10.1039/d1md00195g.
Texto completoMukherjee, Joydeep, Ajay Pandita, Chatla Kamalakar, Tor-Christian Johannessen, Shigeo Ohba, Yongjian Tang, Cecilia L. Dalle-Ore, Rolf Bjerkvig y Russell O. Pieper. "A subset of PARP inhibitors induces lethal telomere fusion in ALT-dependent tumor cells". Science Translational Medicine 13, n.º 592 (5 de mayo de 2021): eabc7211. http://dx.doi.org/10.1126/scitranslmed.abc7211.
Texto completoCowley, Phillip M., Barry E. McGuinness, Gillian M. Campbell y Alan Wise. "Abstract 6172: Characterization of a novel series of highly selective PARP1 inhibitors". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 6172. http://dx.doi.org/10.1158/1538-7445.am2023-6172.
Texto completoPommier, Y., S. H. Huang, B. B. Das, A. Renaud, Y. Zhang, S. H. Takeda y J. H. Doroshow. "284 Differential Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors". European Journal of Cancer 48 (noviembre de 2012): 87. http://dx.doi.org/10.1016/s0959-8049(12)72082-8.
Texto completoMalyuchenko, N. V., E. Yu Kotova, O. I. Kulaeva, M. P. Kirpichnikov y V. M. Studitskiy. "PARP1 Inhibitors: Antitumor Drug Design". Acta Naturae 7, n.º 3 (15 de septiembre de 2015): 27–37. http://dx.doi.org/10.32607/20758251-2015-7-3-27-37.
Texto completoKrastev, Dragomir B., Shudong Li, Yilun Sun, Andrew J. Wicks, Gwendoline Hoslett, Daniel Weekes, Luned M. Badder et al. "The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin". Nature Cell Biology 24, n.º 1 (enero de 2022): 62–73. http://dx.doi.org/10.1038/s41556-021-00807-6.
Texto completoGanguly, Bratati, Sonia C. Dolfi, Lorna Rodriguez-Rodriguez, Shridar Ganesan y Kim M. Hirshfield. "Role of Biomarkers in the Development of PARP Inhibitors". Biomarkers in Cancer 8s1 (enero de 2016): BIC.S36679. http://dx.doi.org/10.4137/bic.s36679.
Texto completoMaifrede, Silvia, Margaret Nieborowska-Skorska, Katherine Sullivan-Reed, Yashodhara Dasgupta, Paulina Podszywalow-Bartnicka, Bac Viet Le, Martyna Solecka et al. "Tyrosine kinase inhibitor–induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors". Blood 132, n.º 1 (5 de julio de 2018): 67–77. http://dx.doi.org/10.1182/blood-2018-02-834895.
Texto completoNguyen, Dang Hai, Zhiyan Silvia Liu, Sayantani Sinha, Maxwell Bannister, Erica Arriaga-Gomez, Axia Song, Dawei Zong et al. "Spliceosome Mutant Myeloid Malignancies Are Preferentially Sensitive to PARP Inhibition". Blood 138, Supplement 1 (5 de noviembre de 2021): 322. http://dx.doi.org/10.1182/blood-2021-149688.
Texto completoCaracciolo, Daniele, Francesca Scionti, Giada Juli, Emanuela Altomare, Gaetanina Golino, Katia Todoerti, Katia Grillone et al. "Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma". Haematologica 106, n.º 1 (20 de febrero de 2020): 185–95. http://dx.doi.org/10.3324/haematol.2019.240713.
Texto completoShen, Xiaokun y Zeng Li. "Abstract P5-05-09: Cvl218,a second-generation selective parp inhibitors with strong clinical potential for breast cancer". Cancer Research 82, n.º 4_Supplement (15 de febrero de 2022): P5–05–09—P5–05–09. http://dx.doi.org/10.1158/1538-7445.sabcs21-p5-05-09.
Texto completoLi, Dongyue. "The Recent Advances of PARP Inhibitors in the Treatment of Cancer". Theoretical and Natural Science 3, n.º 1 (28 de abril de 2023): 855–61. http://dx.doi.org/10.54254/2753-8818/3/20220498.
Texto completoAmbur Sankaranarayanan, Ramya, Susanne Kossatz, Wolfgang Weber, Mohsen Beheshti, Agnieszka Morgenroth y Felix M. Mottaghy. "Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes". Journal of Clinical Medicine 9, n.º 7 (6 de julio de 2020): 2130. http://dx.doi.org/10.3390/jcm9072130.
Texto completoGe, Jun, Yu Yin, Yingpeng Li, Yanru Deng y Hui Fu. "Dual-target inhibitors based on PARP1: new trend in the development of anticancer research". Future Medicinal Chemistry 14, n.º 7 (abril de 2022): 511–25. http://dx.doi.org/10.4155/fmc-2021-0292.
Texto completoConceição, Carlota J. F., Elin Moe, Paulo A. Ribeiro y Maria Raposo. "Liposome Formulations for the Strategic Delivery of PARP1 Inhibitors: Development and Optimization". Nanomaterials 13, n.º 10 (11 de mayo de 2023): 1613. http://dx.doi.org/10.3390/nano13101613.
Texto completoNguyen, Dang Hai, Sayantani Sinha, Zhiyan Silvia Liu, Maxwell Henry Bannister, Erica Arriaga-Gomez, Axia Song, Dawei Zong et al. "Abstract 6183: PARP inhibitors preferentially sensitize splicing factor mutant myeloid neoplasms". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 6183. http://dx.doi.org/10.1158/1538-7445.am2023-6183.
Texto completoJuhász, Szilvia, Rebecca Smith, Tamás Schauer, Dóra Spekhardt, Hasan Mamar, Siham Zentout, Catherine Chapuis, Sébastien Huet y Gyula Timinszky. "The chromatin remodeler ALC1 underlies resistance to PARP inhibitor treatment". Science Advances 6, n.º 51 (diciembre de 2020): eabb8626. http://dx.doi.org/10.1126/sciadv.abb8626.
Texto completoTruong, Sarah, Louise Ramos, Beibei Zhai, Jay Joshi, Fariba Ghaidi, Michael M. Lizardo, Taras Shyp et al. "Abstract 6194: A bifunctional inhibitor of PARP and HDAC enzymes with activity in Ewing sarcoma 3D spheroid and metastasis models". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 6194. http://dx.doi.org/10.1158/1538-7445.am2023-6194.
Texto completoDemény, Máté A. y László Virág. "The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host Interactions". Cancers 13, n.º 9 (24 de abril de 2021): 2057. http://dx.doi.org/10.3390/cancers13092057.
Texto completoDallavalle, Sabrina, Salvatore Princiotto, Luce M. Mattio, Roberto Artali, Loana Musso, Anna Aviñó, Ramon Eritja, Claudio Pisano, Raimundo Gargallo y Stefania Mazzini. "Investigation of the Complexes Formed between PARP1 Inhibitors and PARP1 G-Quadruplex at the Gene Promoter Region". International Journal of Molecular Sciences 22, n.º 16 (14 de agosto de 2021): 8737. http://dx.doi.org/10.3390/ijms22168737.
Texto completoWang, Luyao, Chao Liang, Fangfei Li, Daogang Guan, Xiaoqiu Wu, Xuekun Fu, Aiping Lu y Ge Zhang. "PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs". International Journal of Molecular Sciences 18, n.º 10 (8 de octubre de 2017): 2111. http://dx.doi.org/10.3390/ijms18102111.
Texto completoHiroki, Haruka, Masatoshi Takagi, Yuko Ishi, Jinhua Piao y Tomohiro Morio. "PARP Inhibition Sensitize BCR-ABL1 Positive Cel". Blood 134, Supplement_1 (13 de noviembre de 2019): 3367. http://dx.doi.org/10.1182/blood-2019-127853.
Texto completoTobin, Lisa A., Aaron P. Rapoport, Ivana Gojo, Maria R. Baer, Alan E. Tomkinson y Feyruz V. Rassool. "DNA Ligase III Alpha and (Poly-ADP) Ribose Polymerase (PARP1) Are Therapeutic Targets in Imatinib-Resistant (IR) Chronic Myeloid Leukemia (CML)." Blood 114, n.º 22 (20 de noviembre de 2009): 853. http://dx.doi.org/10.1182/blood.v114.22.853.853.
Texto completoTruong, Sarah, Beibei Zhai, Fariba Ghaidi, Louise Ramos, Jay Joshi, Dennis Brown, Neil Sankar et al. "Abstract 1058: Evaluation of a novel class of bifunctional DNA alkylating agent and PARP inhibitor". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 1058. http://dx.doi.org/10.1158/1538-7445.am2022-1058.
Texto completoEngel, Justin, Madhavi Bandi, Antione Simoneau, Katherine Lazarides, Deepali Gotur, Truc Pham, Shangtao Liu et al. "Abstract 2603: USP1 inhibitor synthetic lethality in BRCA1-mutant cancer is driven by PCNA ubiquitination". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 2603. http://dx.doi.org/10.1158/1538-7445.am2022-2603.
Texto completoGuibbal, Florian, Samantha L. Hopkins, Anna Pacelli, Patrick G. Isenegger, Michael Mosley, Julia Baguña Torres, Gemma M. Dias et al. "[18F]AZD2461, an Insight on Difference in PARP Binding Profiles for DNA Damage Response PET Imaging". Molecular Imaging and Biology 22, n.º 5 (27 de abril de 2020): 1226–34. http://dx.doi.org/10.1007/s11307-020-01497-6.
Texto completoWray, Justin, Elizabeth A. Williamson, Sudha B. Singh, Yuehan Wu, Christopher R. Cogle, David M. Weinstock, Yu Zhang et al. "PARP1 is required for chromosomal translocations". Blood 121, n.º 21 (23 de mayo de 2013): 4359–65. http://dx.doi.org/10.1182/blood-2012-10-460527.
Texto completoTutt, ANJ. "Abstract ES6-4: Parp inhibitors for brca1/2mutation associated breast cancer". Cancer Research 82, n.º 4_Supplement (15 de febrero de 2022): ES6–4—ES6–4. http://dx.doi.org/10.1158/1538-7445.sabcs21-es6-4.
Texto completo